Severe renal Fanconi and management strategies in Arthrogryposis-Renal dysfunction-Cholestasis syndrome: a case report by Rosales, A et al.
CASE REPORT Open Access
Severe renal Fanconi and management
strategies in Arthrogryposis-Renal
dysfunction-Cholestasis syndrome: a case
report
Alejandra Rosales1,2, Maissa Mhibik3, Paul Gissen3, Oscar Segarra4, Susana Redecillas4 and Gema Ariceta1*
Abstract
Background: Arthrogryposis-Renal dysfunction-Cholestasis syndrome (ARC, MIM#208085) is a rare multisystem
disease due to mutations in the VPS33B and VIPAR genes, both involved in maintaining apical-basolateral cell
polarity. The correlation between mutations and phenotype in the ARC Syndrome is not well described. We report
on a 6 year old patient who presented with severe renal Fanconi as first manifestation of ARC related to a
combined de novo mutation in the VPS33B gene.
Case presentation: A 6 year old girl presented during the first year of life with severe renal Fanconi as the first
manifestation of ARC-Syndrome. This case presents all defining features of ARC syndrome (including liver, skin and
articular manifestations) with predominantly renal impairment at presentation. This novel mutation may be
associated with a pronounced renal phenotype in ARC. Furthermore, we report on the successful use of LDL-
Apheresis and biliodigestive derivation for treatment of cholestatic pruritus with encouraging results.
Conclusion: ARC is a heterogeneous disorder with early mortality. This case report contributes to a better
understanding of this rare disorder, describes a novel mutation in the VPS33B gene and presents an innovative
rescue treatment approach.
Keywords: Arthrogryposis-Renal failure-Cholestasis syndrome (ARC), VPS33B, VIPAR, Proximal tubular acidosis, Renal
Fanconi, Ichthyosis, Cholestasis, Pruritus, LDL-apheresis
Background
Arthrogryposis-Renal dysfunction-Cholestasis syndrome
(ARC, MIM#208085) is a rare multisystem disease due
to mutations in the VPS33B and VIPAR genes, both
involved in maintaining apical-basolateral cell polarity.
VPS33B is involved at multiple stages of regulation of
vesicular membrane fusion and intracellular trafficking.
Cell polarity is crucial for the function of proximal tubu-
lar cells (PTC) and altered distribution of apical proteins
could lead to proximal tubule dysfunction and renal
Fanconi syndrome (RFS) in ARC patients [1]. We report
on a (now 6 year old) patient who presented with
complete RFS as first manifestation of ARC related to a
combined de novo mutation in the VPS33B gene.
Case report
The patient manifested at 2 months of age with fever and
irritability. The girl, born at term, was initially clinically
unremarkable apart from bilateral vertical talus. A normal
karyotype was found at prenatal testing. The parents, who
were not consanguineous, reported a positive family his-
tory for a de novo mutation in the PAX 2 gene (cousin).
At the age of 2 months, initial investigations showed
normal blood count and biochemistry (serum glucose
90 mg/dL, Urea 13 mg/dL, Creatinine (Cr) 0.3 mg/dL,
normal electrolytes -Na 139.3 mmol/L, K 4.8 mmol/L, Cl
107 mmol/L-, Calcium 10.5 mg/dL, P 4.7 mg/dL), apart
from reduced serum uric acid (1 mg/dL) and increased
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alkaline phosphatase (1567 U I/L). In addition, urine dip-
stick demonstrated glycosuria and proteinuria. Low
urine osmolarity (UOsm 175 mOsm/kg) and estimated
glomerular filtration rate (eGFR) of 30.8 mL/min/
1.73m2 were observed. Uranalysis showed RFS with
glycosuria (Uglucose/Cr 13.6 mg/mg), hyperphospha-
turia (19.9 mg/kg/day), low phosphate reabsorption
(TRP 77.46%, TmP/GFR 3.32 mg/dL), hypercalciuria
(UCa/Cr 0.57 mg/mg; VCa 7 mg/kg/day) with low mo-
lecular weight proteinuria and global aminoaciduria
(Uprotein/Cr 7.7 mg/mg; V protein 36.1 mg/m2/h,
β2microgb 30 mg/m2/h, MAU/Cr ratio 0.6 mg/g) in
the absence of sodium wasting (C.Na 0.44%) or meta-
bolic acidosis (pH 7.40, pCO2 45.2 mmHg, Bicarbonate
27.4 mmol/L). Cystinosis, the most common cause of
RFS, could be rapidly ruled out after establishing the
presence of a normal leukocyte cystine level. Other causes
of inherited RFS were excluded. Renal ultrasound (US)
demonstrated moderately hyperechogenic normal sized
but abnormally structured kidneys (Patient clinical charac-
teristics are described in Table 1).
Over the first year of life, the patient suffered from in-
creasing severity of RFS with overt polyuria (6 mL/kg/h),
proteinuria, hypercalciuria and stagnation in weight gain.
It came to recurrent severe episodes of diarrhoea with
vomiting, dehydration and considerable electrolyte de-
rangements: high fluid losses made management challen-
ging, requiring frequent hospitalization. In order to fulfil
nutritional requirements, and to replace fluid- and elec-
trolyte losses, tube feeding and finally gastrostomy became
necessary. Added to these problems was the impaired
ability to concentrate urine, as previously mentioned. At
this stage the presence of overt RFS, female gender, and
progressive CKD, was regarded as sufficient explaination
for the overall clinical picture, and primary nephrogenic
diabetes genetic testing was not yet considered.
Treatment with indomethacin, hydrochlorothiazide at
low doses, and later on, at 4 years of age, desmopressin,
led to a decrease in urine output, small size hyperecho-
genic kidneys and CKD III became evident, even in the
absence of nephrocalcinosis.
Furthermore, the patient presented with a distinct-
ive phenotype with slight hypertelorism, episodic mild
skin tanning (without jaundice) and bone anomalies
(vertical talus, hip dysplasia), short stature with partial
response to treatment with rHGH. Otoacoustic emis-
sions showed bilateral hypoacusia, a cerebral MRI dis-
played corpus callosum hypoplasia. Blood smear did
not show remarkable findings. However, platelet dys-
function (with normal coagulation tests and platelet
account, but prolonged bleeding time, and reduced
platelet aggregability) was also detected. Bleeding epi-
sodes were observed in the course of minor proce-
dures and could be successfully managed with platelet
transfusions. Platelets were not studied by electron
microscopy.
At the end of the second year of life, progressively, the
patient had developed refractory pruritus that prevented
her from sleeping and provoked severe anxiety, explaining
in part the developmental delay, and bleeding episodes
Table 1 Summary of patient clinical characteristics
Renal involvement
Renal Fanconi
Presentation: Serum Biochemistry: glucose 90 mg/dL, Urea 13 mg/dL,
Creatinine (Cr) 0.3 mg/dL, normal electrolytes -Na 139.3 mmol/L,
K 4.8 mmol/L, Cl 107 mmol/L-, Calcium 10.5 mg/dL, P 4.7 mg/dL, eGFR
30.8 ml/min/1.73m2, diuresis 2.6 ml/kg/h, urine osmolarity 175 mOsm/kg,
glycosuria (Uglucose/Cr 13.6 mg/mg) hyperphosphaturia 19.9 mg/kg/day,
TRP 77.46%, TmP/GFR3.32 mg/dL, hypercalciuria 7 mg/kg/d, UCalcium/
creatinine ratio 0.57 mg/mg proteinuria Uprot/Cr 7.7; β2microgb 30 mg
/m2/h, MAU/Cr ratio 0.6 mg/g, aminoaciduria C.Na 0.44% Absence of
metabolic acidosis
Recurrent episodes of dehydration and decompensation of renal
Fanconi
Carnitine deficiency
Serum Cu within normal limits
Secondary Hyperparathyroidism
Small kidneys, abnormal structure, absence of nephrocalcinosis
since 2 years of life
















Cholestasis (increased serum bile acids with normal bilirubin)
Skin involvement




Recurrent Sepsis caused by Staphylococcus aureus
Bleeding episodes, platelet dysfunction (prolonged bleeding time,
reduced aggregability)
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due continuous scratching. In addition, recurrent skin
infections and several bacteraemia episodes due to
Staphylococcus aureus occurred and were successfully
treated with parental antibiotics. Over time, she developed
increasing cutaneous changes in terms of ichthyosis, char-
acteristically mainly involving feet and hands, nails and
with time plantar and palmar oedema (Fig. 1). Skin biopsy
showed pronounced hyperkeratosis.
In addition to remarkable skin manifestations, during
those first 2 years of life, the patient presented with an
intermittent transaminitis not attributable to indomethacin
(ASAT max~1000UI/L, ALAT max~800UI/L, Gamma-GT
normal), without jaundice but persistently normal serum
bilirubin levels. Global liver function and ultrasound
remained normal. However, remarkable elevation of total
bile acids (tBA) (> 100 μmol/L) in plasma compatible with
severe cholestasis was detected, which explained patient’s
severe pruritus and partial response to bile salts binders as
Cholestyramine. In summary, our patient presented with
all of the characteristic signs and symptoms of ARC
(summarized in Table 1).
The clinical suspicion of ARC Syndrome was con-
firmed through genetic analysis which showed two de
novo mutations in the VPS33B gene: an heterozygous
mutation (intron 16–17) c.1225 + 5G > Cp.(?) (associated
to moderate phenotype) [1], and second novel heterozy-
gous mutation (exon 7) c.440_499del p.(Pro147Argfs*4)
(premature stop codon, severe mutation, not yet de-
scribed) (analysis performed at the MRC Laboratory for
Molecular Cell Biology, University College London, UK,
by manuscript authors Maissa Mhibik and Paul Gissen).
The patient is now 6 years old, with impaired renal
function - eGFR of ~ 30 mL/min/1, 73 m2 - and severe
RFS with polyuria requiring high amounts of fluids and
electrolytes. Skin lesions and pruritus remain one of the
leading symptoms with persistent transaminitis and nor-
mal liver synthesis function. Various treatment approaches
(including barbiturates and antipsychotics) led to no suc-
cess, but administration of high doses of ursodeoxycholic
acid could achieve a partial response, supporting the
pathogenic role of cholestasis in dermatologic abnormal-
ities. As a proof of concept that removal of bile acids
could improve severe pruritus and skin manifestations [2],
at the age of 5 years, the child started treatment with
LDL-apheresis using an immunoadsorption based method
(Life18TM, LDL-Pro Columns, Miltenyi Biotec). The
procedure was performed twice weekly for a total of 24
sessions, using regional anticoagulation with citrate. Each
session lasted 1.5 h and a volume equivalent to 2
patient-volemia was treated. The treatment was perfectly
tolerated and no complications, especially in terms of
bleeding, were observed. A significant decrease in tBA
levels before and after treatment with LDL-apheresis was
achieved (p < 0.001 (t test), Table 2), with median
pre-treatment tBA of 41 μmol/L (IQR 19.5) and
post-treatment tBA of 20.7 μmol/L (IQR 8.4). Reduction
of the pruritus could be achieved, and skin lesions
improved partially too, under pharmacological treatment
Fig. 1 Skin manifestations. a at presentation. b before biliodigestive anastomosis. c after biliodigestive anastomosis
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with ursodesoxycholic acid. Driven by that result, in Janu-
ary 2017 an entero-biliary anastomosis was performed.
Shortly after the intervention we observed a significant
improvement of pruritus, regression of skin lesions, and
significant improvement in quality of life (Fig. 1).
Discussion
Polarization of human epithelial cells is crucial for ad-
equate organ development and function. The PT is the
site of reabsorption of valuable solutes. Disruption of
endocytosis and intracellular trafficking can lead to im-
paired PT function and present as RFS. The VPS33B
gene is involved at multiple stages in the regulation of
vesicular membrane fusion and trafficking, including
maturation and control of endosomes [1, 3]. In the PT,
disturbed endosome maturation could affect the apical re-
cycling pathway [4]. Most ARC patients present certain
grade of tubular dysfunction with proteinuria, aminoacid-
uria, glycosuria and tubular acidosis which can worsen
with intercurrent infectious events [1]. The correlation
between genotype and phenotype in ARC is not well
described. We present a 6-year old patient with RFS as
first manifestation of ARC and two different de novo mu-
tations in the VPS33B gene. The VPS33B c.1225 + 5G-C
mutation seems to affect the ability of the complexes to
colocalize properly on tubular-vesicular recycling mem-
branes, which would impair, at least partially, their cellular
functioning [3, 4]. No reports describing the second and
novel identified mutation have been found so far ((exon 7)
c.440_499 del p. (Pro147Argfs*4)). This mutation may be
severe since it introduces a premature stop codon and
could be related to a pronounced renal phenotype of ARC
syndrome.
Most reported ARC cases describe severe forms and
early mortality [5]. Gissen et al. report on 62 ARC pa-
tients of 35 families, none of the patients was older than
20 months at the time of publication. However, it has
been described that affected individuals with the VPS33B
c.1225 + 5G-C mutation, may present a somehow milder
phenotype [1]. Despite disease severity, and multidiscip-
linary management, our patient survival beyond 6 years
of age could be partially attributed to that. Besides se-
vere infections, bleeding is one of the most relevant
factors affecting mortality in ARC patients [3], and
indeed constituted one major morbidity factor in our pa-
tient before her specific diagnosis was identified. VPS33B
is involved in the formation of precursor alpha-granules
of platelets (both stored and membrane components)
and presentation is similar to gray platelet syndrome [6].
Currently we are avoiding bleeding complications using
preventive platelet transfusions before invasive procedures
in our patient, or as early treatment of haemorrhage epi-
sodes, with good outcome.
ARC patients present a variety of skin and musculoskel-
etal alterations and seem to share a peculiar phenotype.
VPS33B plays a role in collagen maturation (important
component of the basal membrane, also crucial in the de-
velopment of cell polarity) and keratinocyte differentiation
(metabolism of lamellar bodies) [7, 8]. Furthermore,
disturbed hepatocyte polarity and elevation of biliary acids
are involved in the development of skin lesions and prur-
itus. Recently, we published the beneficial results of
LDL-apheresis in this patient, as an example of potential
indication of the procedure in patients with refractory
cholestatic pruritus [9]. This case showed drastic im-
provement of skin lesions after biliodigestive anasto-
mosis (Fig. 1). Similar results were already reported
after liver transplantation in a 12 year old ARC patient
[10]. Nevertheless, a previous report shows response of
pruritus to cutaneous biliary diversion but persistence
of severe skin lesions [3].
Conclusion
ARC is a heterogeneous disorder with early mortality.
This case report contributes to a better understanding
of this rare disorder, describes a novel mutation in the
VPS33B gene which could be associated to a pronounced
renal phenotype in ARC-Syndrome. Furthermore, we
present LDL-apheresis as an innovative rescue treat-
ment approach for cholestasis associated pruritus in
ARC-Syndrome.
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tBAa 87.3 (48–117) 41 (32.5–52) 20.7 (17–25.4) 23.6 (22.6–28)
Colesterol 102 (99–132.6) 148 (142–159) 61 (59–68.5) 126 (118.5–143)
LDL 77 (73.5–80.5) 77 (73–78) 16 (15.5–17.5) 68 (58.5–77.5)
HDL 33 (32–34.5) 44 (43–49) 28 (27.5–33.5) 26.5 (23.75–27.25)
aReference values: tBA < 10 μmol/L
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